Moderna’s COVID-19 vaccine shows efficacy of 94.5% in Phase 3 trial
Moderna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read moreModerna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read moreCureVac, a German biopharmaceutical company developing innovative medicines based on messenger ribonucleic acid (mRNA), announced that its mRNA-based COVID-19 vaccine
Read morePfizer and BioNTech have announced their mRNA-based vaccine candidate for COVID-19, tested in a Phase 3 study involving 43,538 participants,
Read moreNovavax has announced the expansion of its Gaithersburg, Maryland campus to support global vaccine development through the addition of two
Read moreSanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreEli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreAmerican biotech Moderna has signed an agreement with the Ministry of Public Health to supply Qatar with its mRNA COVID-19
Read moreAstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read moreInterim analysis of the J&J COVID-19 vaccine candidate (JNJ-78436735) in the ongoing Phase 1/2a clinical trial has shown that a
Read moreThe World Health Organization (WHO) and the Democratic Republic of Congo (DRC) government announced on June 25 that the second-largest
Read more